DelveInsight has launched a new report on “Carcinoid Syndrome – Market Insights, Epidemiology, and Market Forecast-2032”.
Some of the key facts of the Carcinoid Syndrome Market Report:
- NETs represent the second most common prevalent gastrointestinal cancers with a prevalence of 171,321 and an annual incidence rate of 6.98 per 100,000 as per the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute.
- The frequency of CS in the US Surveillance, Epidemiology, and End Results (SEER) database (2000–2011) was reported to be 19% in patients >65 years, with an increasing incidence over the years mirroring the general increase in frequency of Neuroendocrine neoplasms (NENs).
- As per NHS, About 4,000 people are diagnosed with a neuroendocrine tumor each year in the UK, but not everyone with a tumor will have carcinoid syndrome.
Key benefits of the report:
- Carcinoid Syndrome market report covers a descriptive overview and comprehensive insight of the Carcinoid Syndrome Epidemiology and Carcinoid Syndrome market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Carcinoid Syndrome market report provides insights on the current and emerging therapies.
- Carcinoid Syndrome market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Carcinoid Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Carcinoid Syndrome market.
Got queries? Click here to know more about the Carcinoid Syndrome Market Landscape.
Carcinoid Syndrome Overview
Carcinoid Syndrome (CS) refers to a combination of symptoms, physical manifestations, and abnormal laboratory findings. Carcinoid syndrome is seen in individuals who have an underlying carcinoid tumor that has spread to the liver. Carcinoid tumors are well-differentiated neuroendocrine tumors with secretory properties, releasing serotonin, along with a number of other active peptides. These tumors can arise anywhere along the primitive gut and are therefore found in the bronchial tree (airways) and along the gastrointestinal tract. The tumor cells can also migrate (metastasize) to the liver.
Carcinoid Syndrome Market
The dynamics of the Carcinoid Syndrome market is anticipated to change in the coming years owing to the expected launch of emerging therapies by companies such as Aquestive Therapeutics, Crinetics Pharmaceuticals, and others during the study period 2019-2032.
Carcinoid Syndrome Pipeline Therapies and Key Companies
- AQST-305-SF: Aquestive Therapeutics
- Paltusotine: Crinetics Pharmaceuticals
Carcinoid Syndrome Market Drivers
- Advent of new concepts in pathophysiology and therapeutic interventions
- Growing R&D
- Advances in the molecular pathogenesis of NENs
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Carcinoid Syndrome Patient Share (%) Overview at a Glance
5. Carcinoid Syndrome Market Overview at a Glance
6. Carcinoid Syndrome Disease Background and Overview
7. Carcinoid Syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Carcinoid Syndrome
9. Carcinoid Syndrome Current Treatment and Medical Practices
10. Unmet Needs
11. Carcinoid Syndrome Emerging Therapies
12. Carcinoid Syndrome Market Outlook
13. Country-Wise Carcinoid Syndrome Market Analysis (2019–2032)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Carcinoid Syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Carcinoid Syndrome Pipeline
“Carcinoid Syndrome Pipeline Insight, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Carcinoid Syndrome market. A detailed picture of the Carcinoid Syndrome pipeline landscape is provided, which includes the disease overview and Carcinoid Syndrome treatment guidelines.
Carcinoid Syndrome Epidemiology
DelveInsight’s ‘Carcinoid Syndrome Epidemiology Forecast to 2032’ report delivers an in-depth understanding of the disease, historical and forecasted Carcinoid Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/